Abstract
Lysosomes communicate through cholesterol transfer at endoplasmic reticulum (ER) contact sites. At these sites, the Niemann Pick C1 cholesterol transporter (NPC1) facilitates the removal of cholesterol from lysosomes, which is then transferred to the ER for distribution to other cell membranes. Mutations in NPC1 result in cholesterol buildup within lysosomes, leading to Niemann-Pick Type C (NPC) disease, a progressive and fatal neurodegenerative disorder. The molecular mechanisms connecting NPC1 loss to NPC-associated neuropathology remain unknown. Here we show both in vitro and in an animal model of NPC disease that the loss of NPC1 function alters the distribution and activity of voltage-gated calcium channels (CaV). Underlying alterations in calcium channel localization and function are KV2.1 channels whose interactions drive calcium channel clustering to enhance calcium entry and fuel neurotoxic elevations in mitochondrial calcium. Targeted disruption of KV2–CaV interactions rescues aberrant CaV1.2 clustering, elevated mitochondrial calcium, and neurotoxicity in vitro. Our findings provide evidence that NPC is a nanostructural ion channel clustering disease, characterized by altered distribution and activity of ion channels at membrane contacts, which contribute to neurodegeneration.
Similar content being viewed by others
Introduction
Cholesterol, an essential sterol, is particularly abundant in the brain1,2 where it fulfils important biophysical and signaling functions that affect ion permeability, cellular signaling, and general programs of transcription (for general review see refs. 1,3,4,5,6,7). Given the importance of maintaining cholesterol homeostasis for controlled neuronal function, it is not surprising that mutations that disrupt cholesterol production or transport result in severe abnormalities of the central nervous system (CNS) and neurodegeneration8,9.
In the brain, all cholesterol is made locally10 with neurons drawing their homeostatic requirements from two sources (i) de novo synthesis in the Endoplasmic Reticulum (ER), and (ii) uptake of the externally derived cholesterol-conjugated lipoproteins. External cholesterol is imported into neurons in a receptor-dependent manner and trafficked to late endosomes /lysosomes11. At these vesicular structures, the Niemann Pick type C (NPC) proteins are key players in mobilizing cholesterol to the ER and other cellular membranes12,13. Specifically, following liberation by acidic lipases in the lysosome lumen, cholesterol binds NPC2, which subsequently interacts with the transmembrane NPC1 cholesterol transporter to facilitate the egress of cholesterol across the lysosome membrane to its cytoplasmic leaflet before subsequent transfer to the ER at lysosome–ER Membrane Contact Sites (MCSs). The importance of the NPC1 protein is clear; physiologically, it is a key gatekeeper for cholesterol homeostasis and in doing so tunes mTORC1 activity, lipid transfer at membrane contact sites, and Ca2+ signaling14,15,16,17. Pathophysiologically, missense mutations in NPC1 lead to the progressive neurodegenerative disorder NPC disease. This terminal condition has no cure and is characterized by the progressive neurodegeneration of several brain regions and a host of devastating symptoms including seizures, psychiatric problems, and dementia. Despite its ubiquitous expression, key role in cholesterol transport, and fundamental requirement for human health, the molecular mechanism(s) linking loss of NPC1 function to neurodegeneration are unknown.
A key mechanism through which the lysosome communicates instructions to other organelles is through physical membrane contacts. These intracellular synapses are intimate sites (~10–30 nm) of membrane contact between two or more organelles18,19,20,21,22 that use lipids and Ca2+ as “currency” to communicate information. A key signaling lipid that is transferred at ER–lysosome MCSs is cholesterol. The NPC1 protein not only influences cholesterol transport at lysosome–ER MCSs but is also a master regulator of other MCSs within mammalian cells14,16,17,23,24. Loss of function or disease mutations in NPC1 cholesterol transporter results in the remodeling of ER–lysosome14,15, ER–Golgi16 and ER–Mitochondria17 MCSs to influence mTORC1 signaling, anterograde trafficking to the Plasma Membrane (PM), and mitochondrial Ca2+, respectively. That said, there is little information as to how lysosomal cholesterol transport alters the molecular choreography of neuronal ER–PM junctions. This is important because (i) 40–90% of cellular cholesterol is found in the PM7,25, therefore disruption of NPC1-mediated cholesterol homeostasis would be expected to result in modification of ER–PM MCSs, and (ii) ER–PM MCSs are critical platforms for regulating lipid and Ca2+ homeostasis in neurons2,26,27,28,29,30,31. Despite such importance, we do not know how the loss of cholesterol transport from the lysosome alters ER–PM MCSs, which proteins within these contacts have altered distribution/activity, and the cellular consequences of such changes.
In neurons, a key regulator of ER–PM MCSs is the voltage-gated potassium channel KV2.1. Gating of this voltage-dependent ion channel provides an inhibitory brake on excitability32,33. However, over the past few years it has been appreciated that a subset of non-conducting KV2 ion channels perform a physical function by generating ER–PM junctions through an association between their C-terminus and ER-localized VAP proteins in a phosphorylation-dependent manner26,34,35. Moreover, at ER–PM MCSs, KV2 channels physically interact with and cluster Ca2+ signaling proteins like voltage-gated L-type Ca2+ channels (CaV1)2,31,36. CaV1 channels are key neuronal Ca2+ signaling proteins which serve as a principal route of Ca2+ entry at depolarized membrane potentials. Such biophysical properties give CaV1 a prominent role in neuronal excitability and gene expression, which are crucial for neuronal signaling and synaptic plasticity37. Moreover, several neurodegenerative diseases are characterized by excessive Ca2+ influx through CaV1 channels38,39 with their targeted knockdown or inhibition being neuroprotective40,41,42. While KV2-mediated targeting and regulation of CaV1 channels at ER–PM MCSs serves a physiologically important role in neurons, there is no information on how this form of regulation may be altered in disease, including how lysosomal cholesterol may regulate KV2 clustering to tune excitability and Ca2+ signaling at ER–PM MCSs to impact neurodegeneration in NPC disease.
In this current study, we report that loss of NPC1 function results in phosphorylation-dependent increases in KV2.1 clustering at the PM. We show that enhanced Kv2.1-containing ER-PM MCSs are enriched in SERCA, CaV1.2, and RyR resulting in enhanced Ca2+ signaling at KV2.1 associated ER–PM nanodomains. In addition to remodeling of ER–PM MCSs, we also show that Ca2+ handling proteins at ER–Mitochondrial MCSs are modified following loss of NPC1 function. Collaboratively, this molecular transformation of MCSs leads to deviant elevations in mitochondrial Ca2+ and neurotoxicity. Importantly, we demonstrate that uncoupling upstream KV2–CaV1 interactions rescues mitochondrial Ca2+ and neurotoxicity and thus represents a potential therapeutic target in NPC1 disease. Collectively, these data demonstrate that NPC is a nanostructural ion channel clustering disease with altered ion channel distribution/activity at MCSs contributing to neurodegeneration.
Results
Loss of NPC1 function increases voltage-dependent Ca2+ entry and CaV1 channel clustering in isolated neurons
The opening of voltage-gated Ca2+ channels (CaV) permits movement of Ca2+ down its concentration gradient to increase intracellular Ca2+ levels and represents a major mechanism through which neurons translate electrical signals into biochemical ones. Elevations in Ca2+ are tightly regulated in mammalian neurons43,44 with dysregulation linked to several neuropathologies45,46,47,48,49,50,51. Recently, we have reported that NPC1 inhibition, NPC1 mutations (NPC1I1061T) or NPC1 knockout (NPC1−/−) neurons are hyperexcitable, firing significantly more Action Potentials (APs) compared to age and sex-matched Wild-Type (WT) littermates52. Given the importance of the membrane potential for controlling Ca2+ entry through CaV channels53, we wanted to test if NPC1 loss of function alters voltage-dependent Ca2+ activity. To test this hypothesis, we incubated cortical neurons overnight using a specific pharmacological inhibitor of NPC154,55 (U18666A; referred to as U18 hereafter), which increases spontaneous and stimulated voltage responses as well as internal cholesterol accumulation (Figure S1A)52, and loaded cells with the cytosolic Ca2+ dye, Fluo-4. Quantitative analysis from Fluo-4 time-series experiments revealed that U18 treatment increased the amplitude and frequency of both spontaneous and stimulated (40 V, 1 Hz) elevations in Fluo-4 intensity relative to controls (Fig. 1A–D). Interestingly, the relative change in Fluo-4 intensity between basal activity and following stimulation was decreased compared to control (ΔF40V 1Hz/ΔF0-25s in Fig. 1D), suggesting a narrower dynamic range for Ca2+ signaling in NPC. Furthermore, preventing AP generation by treatment with the voltage-gated sodium channel blocker Tetrodotoxin (TTX) not only abrogated any NPC1-driven increase in basal and electrically evoked Fluo-4 intensities, but also reduced both spontaneous and stimulated cytosolic Ca2+ amplitude elevations compared to control neurons (Fig. S1B).
Increased frequency of voltage-dependent Ca2+ entry is likely driven by the hyperexcitability phenotype in NPC disease52. However, increases in the amplitude of Ca2+ events suggested to us that in addition to enhanced hyperexcitability, CaV channel expression and/or distribution may be altered following the loss of NPC1 function. A salient feature of CaV1 channels in neurons, cardiac myocytes, and smooth muscle is that their activity is regulated by clustering (for review see ref. 56), such that adjacent channels can functionally interact with one another permitting cooperative gating57,58,59,60,61. As a result, the activity of physically interacting channels in a cluster is driven by the highest open probability channel, thus enhanced channel clustering facilitates the amplification of Ca2+ currents. To test if NPC1 loss of function alters CaV distribution we treated cortical with U18 before fixing and immunolabeling for CaV1.2 and performing super-resolution AiryScan or single molecule localization TIRF microscopy (super-resTIRF). Quantification of total intensity, cluster density, and cluster size from AiryScan confocal regions close to the PM demonstrated that U18-treatment enhanced CaV1.2 clustering in both the soma and dendrites (Fig. 2A). Analysis of super-resTIRF localization maps (resolution of 30 nm62) further corroborated our AiryScan analysis that U18-treatment increased the size and number of PM CaV1.2 clusters (Fig. 2B). Moreover, nearest neighbor cluster distance analysis revealed that CaV1.2 clusters are in closer spatial proximity following NPC1 loss of function (Fig. 2B).
In addition to CaV1.2, cortical neurons have other L- and P/Q-type CaV channels that contribute to voltage-dependent Ca2+ entry. To test if these CaV channel isoforms are also altered, we immunolabeled cortical neurons with antibodies against CaV1.3 or CaV2.1 and quantified their distributions at the PM using super-resolution microscopy. CaV1.3 cluster sizes were significantly increased upon U18 treatment while the total fluorescence intensity, number of clusters and spatial proximity between adjacent channels was unaltered in the somatic region of neurons (Fig. 2C, D). Unlike the soma, CaV1.3 cluster size and density in dendrite regions remained unchanged while total fluorescence intensity significantly decreased (Fig. 2C). In contrast to CaV1.2 and CaV1.3, quantification of CaV2.1 revealed a significant reduction in cluster size and intensity with no significant difference in cluster number at the soma, while Cav2.1 clustering in dendrites remained unaltered by U18 (Fig. S2). Collectively, these data provide evidence that loss of NPC1 function facilitates clear and broad alterations in CaV1 channel distribution with significant increases in the size of CaV1.2 and CaV1.3 channel clusters in the cell soma.
KV2.1 clustering is enhanced following loss of NPC function in-vitro and in animal models of NPC disease
Having demonstrated that the NPC1 cholesterol transporter influences the distribution of PM CaV channels, we next wanted to determine the molecular mechanism that increases somatic CaV1.2 and CaV1.3 channel clustering. To begin, we tested if a simple increase in CaV1.2 protein levels could account for increases in channel clustering. To that end, we extracted protein from cortical neurons cultured for 6-8 Days In Vitro (DIV) and found that total CaV1.2 protein levels were similar between control and U18-treated neurons (Fig. S3A) suggesting a simple increase in protein expression is unlikely to underlie increases in PM CaV channel distribution.
Recently, voltage-gated KV2.1 potassium channels have been demonstrated to organize neuronal CaV1 channels, impacting their distribution and activity in specific somatic microdomains2,31. Based on our observations that somatic CaV1.2 and CaV1.3 channel clusters are increased in NPC disease conditions, we tested if KV2.1 channels also had altered distribution. Confocal and super-resTIRF analysis from fixed cortical neurons immunolabeled for KV2.1 revealed that the total fluorescence intensity, number of clusters, and cluster size were all increased in the PM from somatic and dendritic regions of U18-treated neurons relative to control (Fig. 3A). Additionally, in-depth analysis of super-resTIRF maps determined that not only are KV2.1 channel clusters larger, but they are closer together with U18 decreasing nearest neighbor distance between adjacent KV2.1 channel clusters (Fig. 3B). Like CaV1.2 channels, total levels of KV2.1 expression remained constant between control and U18 conditions (Fig. S3A).
Next, to test if animal models of NPC1 disease also have altered neuronal KV2.1 distribution, we fixed, sectioned, and immunolabeled brain sections from WT and NPC1I1061T (most prevalent disease mutation) mice for KV2.1. Similar to treatment with U18, mice harboring the NPC1I1061T mutation displayed increased KV2.1 clustering in cortical (Fig. 3C) and hippocampal (Fig. S3B) pyramidal neurons, and cerebellar Purkinje neurons (Fig. 4D). Therefore, like CaV1.2, KV2.1 clusters are larger and more abundant in NPC disease.
NPC1 loss of function increases KV2.1–CaV1.2 colocalization in vitro and in vivo
Loss of NPC1 function increases CaV1.2 (Fig. 2) and KV2.1 (Fig. 3) clustering in somatic regions of neurons. Given that these two channels physically interact31, we used two complementary approaches to test if loss of NPC1 function alters the proximity of KV2.1–CaV1.2 channel complexes. First, using super-resTIRF imaging we quantified the relative distribution between CaV1.2 and KV2.1 channel complexes. Figure 4A shows that around 0.05% of neuronal somatic pixels were positive for both CaV1.2 and KV2.1 in control conditions at this enhanced resolution. Inhibition of NPC1 led to a 3-fold increase in the number of somatic pixels positive for both CaV1.2 and KV2.1, with increases in the average size of CaV1.2–KV2.1 clusters (Fig. 4A). Furthermore, NPC1 loss-of-function also reduced the average distance between adjacent CaV1.2–KV2.1 hetero-clusters (Fig. 4A). Identical results were observed in blinded experimental datasets (Fig. S4A, B) and NPC1−/− cells (Fig. S4C). To further elucidate if the physical proximity between CaV1.2 and KV2.1 is altered in NPC1 disease conditions, we performed Proximity Ligation Assays (PLA). The PLA technique allows the detection and quantification of those CaV1.2 and KV2.1 channels that are within 40 nm of one another63. Like super-resTIRF imaging, PLA experiments revealed an increase in the number of CaV1.2–KV2.1 channel clusters within 40 nm of one another, with each hetero-cluster being closer to each other in the neuronal soma following loss of NPC1 function (Fig. 4B).
To corroborate that increased CaV1.2–KV2.1 complexes occur in intact brain regions, we performed multiplexed immunolabeling on cerebellar tissue of WT and NPC1I1061T mutant mice (Fig. 4C). The cerebellum was chosen because Purkinje cells represent another highly vulnerable neuronal population in NPC1 disease64,65. Like isolated cortical neurons, CaV1.2 and KV2.1 channels showed increased spatial proximity in mouse NPC1I1061T Purkinje neurons (Fig. 4C; movie S1). Thus, both NPC1 inhibition and disease mutations increase CaV1.2–KV2.1 complexes.
KV2.1 channels associate with CaV1.2 channels via a Ca2+ Channel Association Domain (CCAD) located in the proximal cytoplasmic C-terminus of KV2.12. To test if CCAD-dependent interactions between KV2.1–CaV1.2 drive increases in CaV1.2 channel clusters following loss of NPC1 function we took advantage of a cell permeant synthetic peptide “HA-TAT-C1aB” (CCAD)66 which selectively uncouples KV2.1–CaV1.2 channel complexes2. Using this synthetic tool, and a corresponding peptide with a scrambled CCAD sequence “TAT-HA-C1aB-Scr” (SCRBL), we compared CaV1.2 distribution in isolated mouse (Fig. 4D, E and Fig. S4B) and rat (Fig. S5A) neurons under control and U18 conditions, as well as NPC1−/− cells (Fig. S4C). Analysis revealed that in all models increases in CaV1.2 density and cluster size were eliminated in the presence of CCAD, but not the Scr control peptide, providing evidence that U18 or NPC1−/− –associated elevations in the size of CaV1.2 clusters are dependent on interactions with KV2.1 channels.
CDK5-dependent phosphorylation of KV2.1 drives NPC1-dependent increases in CaV1.2 clustering in isolated neurons
Clustering of PM KV2.1 channels is regulated by phosphorylation32,67 with protein kinases like Cyclin Dependent Kinase 5 (CDK5) promoting KV2.1 clustering67 (Fig. 5A), and protein phosphatases like calcineurin de-clustering of KV2.132. To test if loss of NPC1 function increases phosphorylation of KV2.1 channels we fixed and immunolabeled neurons with a phospho-specific antibody against the pS603 site of Kv2.1 which has been shown to be sensitive to CDK5 phosphorylation67. Subsequent super-resTIRF analysis revealed the density of somatic KV2.1 pS603 clusters to be significantly increased in U18 treated neurons relative to control (Fig. 5B). To test if CDK5 underlies increased KV2.1 phosphorylation in NPC disease we first measured CDK5 protein expression and found it was similar between control and U18 treated neurons (Fig. 5C). Next, we asked if CDK5 activating proteins p35/p39 have altered expression following loss of NPC1 function. Consistent with a report of increased CDK5 enzymatic activity in NPC disease models68, expression of both p35 and p39 proteins was significantly elevated following inhibition of NPC1 (Fig. 5C). Interactions between CDK5 and p35 promote targeting and anchoring of the enzyme to the plasma membrane69,70; therefore, we performed dual-label super-res imaging for KV2.1 and CDK5 and found the fractional amount of CDK5 overlapping with KV2.1 increased when NPC1 was inhibited (Fig. 5D). Collectively, these experiments support a model whereby NPC1 loss-of-function increases p35/p39 expression which preferentially targets CDK5 to the plasma membrane. Here it is in closer proximity to KV2.1 to increase phosphorylation-dependent clustering of KV2.1 thereby promoting increased KV2.1–CaV1.2 interactions.
Targeting CDK5 rescues clustering phenotypes in NPC disease in vitro
To probe more directly that CDK5 activity drives phosphorylation of KV2.1 to enhance KV2.1–CaV1.2 complexes in models of NPC1 we conducted experiments using the small molecule CDK5 inhibitor, roscovitine (Fig. 6A). Cortical neurons were incubated with U18 and Roscovitine, before being fixed and immunolabeled for CaV1.2 and KV2.1. In agreement with super-res analysis of KV2.1 pS603 (Fig. 5B), U18 treatment significantly increased the area occupied by both CaV1.2 and KV2.1 in somatic and proximal dendrites (Fig. 6B). In contrast, inhibiting CDK5 not only prevented the U18-dependent increases in both KV2.1 and CaV1.2 clustering (Fig. 6B) but also abrogated U18-mediated elevations in CaV1.2–KV2.1 hetero-cluster size and density (Fig. 6B). Interestingly, roscovitine did not alter steady-state KV2.1–CaV1.2 hetero-cluster sizes in control neurons, suggesting a CDK5-independent mechanism for recruitment and binding of KV2.1 to CaV1.2. This is perhaps not surprising given that several protein kinases can phosphorylate KV2.1 at different positions and supports the concept that multiple protein kinases may tune KV2.1–CaV1.2 interactions. As a final test, we began to probe molecular elements upstream of CDK5–p35/p39. To this end, we focused on mTORC1 as it has been shown to be hyperactive in NPC disease15 and is proposed to inhibit AMPK71 leading to increased CDK5 activity72. To test for an upstream role for mTORC1 we treated neurons with a combination of U18 (to inhibit NPC1) and/or Torin-1 (to inhibit mTORC1) before fixing and labeling for CaV1.2 and KV2.1. Subsequent super-res imaging revealed that U18-dependent increases CaV1.2 and KV2.1 clusters were sensitive to mTORC1 inhibition with KV2.1–CaV1.2 nanocomplexes reduced back to control levels (Figure S5B). These data suggest that mTORC1 may be an upstream element controlling KV2.1–CaV1.2 complexes in NPC disease. More experiments are required to determine the precise molecular pathway linking mTORC1 to alterations in KV2.1–CaV1.2 complexes.
KV2.1-associated CaV1.2 influences the formation of ER–PM junctions
Phosphorylation of KV2.1 within its Proximal Restriction and Clustering (PRC) domain generates a noncanonical FFAT (two phenylalanines (FF) in an Acidic Tract) motif that facilitates interactions with ER VAP proteins leading to the formation of ER–PM MCSs34,35. Given the increase in KV2.1 clusters following loss of NPC1 function, we asked if ER–PM MCSs are also altered (Fig. 7A). To begin we performed a volumetric analysis using a live-neuron ER dye to test if basic ER morphology is altered following NPC1 inhibition and determined that ER filament length and density, as well as ER branching density were the same in control and U18-treated neurons (Fig. S6). Therefore, NPC1 inhibition does not appear to result in gross changes to ER morphology. Next, we performed dual-label immunofluorescence against KV2.1 and VAPA/B and determined using super-resTIRF imaging that VAPA/B cluster density, size, and overlap with KV2.1 were all increased when NPC1 was inhibited (Fig. 7B). These data are consistent with increased ER–PM contact sites in NPC disease models. To test this hypothesis, we took advantage of two fluorescent tools: (i) SPLICSS/L-P2AER-PM 73 and (ii) MAPPER74, which enable visualization and quantification of ER–PM MCSs in living neurons. The SPLICSS/L-P2AER-PM tool is based on the split-YFP protein fused to either an ER or PM target so it only emits fluorescence upon self-assembly at the ER–PM interface. A short or long spacer placed at the split-YFP ER targeted protein allows for the study of narrow (8–10 nm) or wide (40–50 nm) ER–PM MCSs73. Transfection of this ER-PM sensor into cortical neurons revealed a punctate distribution within either 40 nm or 10 nm of the TIRF footprint that represents the cortical ER in close apposition to the PM (Fig. 7C, D). Comparison of control and U18-treated neurons demonstrated that loss of NPC1 function resulted in an increase in the amount of ER in close proximity to the PM (Fig. 7C, D). As an alternative approach to quantify changes in ER–PM MCSs we used the MAPPER construct. The MAPPER tool is a GFP-tagged single peptide that contains the transmembrane domain of STIM1 (targeted to the ER) and a polybasic motif of the small G-protein Rit (PM binding)74. The polybasic motif interacts with negatively charged lipids at the cytoplasmic leaflet of the PM and enables visualization of ER–PM contacts between 10 and 25 nm. Like SPLICSS/L-P2AER-PM, expression of MAPPER revealed a punctate distribution when visualized using super-res AiryScan microscopy at a focal plane close to the PM (Fig. 7E). Quantification of MAPPER images determined that MAPPER puncta density and size were both increased in U18-treated neurons at the soma and dendrites (Fig. 7E). Interestingly, when KV2.1–CaV1.2 interactions were disrupted with the CCAD peptide, U18-dependent increases in ER–PM MCSs were partially reversed with decreases in the number and size of MAPPER puncta (Fig. 7E). These data suggest that KV2.1-associated CaV1.2 plays an important role in generating ER–PM MCSs in NPC1 neurons.
NPC1 inhibition remodels Ca2+ handling proteins at ER–PM MCSs to potentiate Ca2+ signaling in vitro
At somatic ER–PM MCSs, in addition to CaV1.2, KV2.1 is in close spatial proximity with several other Ca2+ handling proteins, including Ryanodine Receptors (RyR) and Sacro/Endoplasmic Reticulum Ca2+-ATPase (SERCA)31,75. Considering the increases in KV2.1–CaV1.2 complexes (Fig. 4) and ER–PM MCSs (Fig. 7) observed following the loss of NPC1 function we wanted to determine if RyR and SERCA are enriched at these ER–PM contacts (Fig. 8A). To test if SERCA distribution is altered at KV2.1-forming nanodomains we performed super-resTIRF on neurons fixed and co-immunolabeled for KV2.1 and SERCA. In control and U18-treated neurons SERCA was observed in the TIRF footprint, indicating close spatial proximity to the PM (Fig. S7A). Furthermore, U18 treatment significantly enhanced SERCA cluster area and overlap with KV2.1 (Figure S7A). These data align with previously published results that SERCA expression is significantly increased in NPC disease models23. To assess RyR distribution relative to KV2.1–CaV1.2 domains, we co-immunolabeled for CaV1.2 and RyR with or without U18 treatment to inhibit NPC1. Using super-res AiryScan confocal microscopy we quantified RyR and CaV1.2 distribution at a focal plane close to the PM and found that in addition to expected increases in CaV1.2 cluster size, their proximity to one another increased when NPC1 function is lost (Fig. 8B). On average, there was a 40 % increase in overlapping CaV1.2–RyR pixels in the soma and a doubling of overlapping pixels in the dendrites of NPC loss of function neurons relative to control. These findings reveal that both RyR and SERCA are enriched at KV2.1 associated ER–PM MCSs following the loss of NPC1 function.
Considering the importance of KV2.1 for tuning ER–PM Ca2+ nanodomains2,31 and the significant reorganization of KV2.1–CaV1.2–RyR–SERCA that occurs following loss of NPC1 function, we next wanted to understand if this molecular remodeling results in augmented Ca2+ signaling at these KV2.1 associated ER–PM contacts. To monitor and quantify Ca2+ signaling at KV2.1 ER–PM MCSs we took advantage of a recently described GCaMP Ca2+ sensor, GCaMP3-Kv2.1P4O4W which is GCaMP3 appended to the N-terminus of nonconducting KV2.131. Transfection of GCaMP3-Kv2.1P4O4W into cortical neurons resulted in its distinct localization to ER–PM MCSs (Fig. 8C). Using TIRF microscopy to visualize GCaMP3-Kv2.1P4O4W in close apposition to the PM we quantified spontaneous changes in GCaMP3 intensity from neurons expressing low amounts of the Ca2+ biosensor. Analysis of GCaMP3s signals determined that in NPC loss of function neurons, the amplitude of spontaneous Ca2+ signals at KV2.1-forming ER–PM MCSs effectively doubled compared to control (Fig. 8C). To test the role of CaV1.2 channels in facilitating this increase we uncoupled KV2–CaV1 interactions at ER–PM MCS (co-incubation with the CCAD peptide) which resulted in neurons being refractory to U18 and having significantly decreased responses relative to control (Fig. 8C; Movie S2). Similar results were observed when neurons were treated with a cell-penetrating FFAT peptide to uncouple KV2.1 from VAPA/B. Finally, to test if CCAD decreased Ca2+ elevations near KV2.1 due to selective uncoupling of KV2.1–CaV1.2 or due to hyperpolarization in the membrane potential we performed experiments using a genetically encoded voltage indicator (ArchLight-Q23976). High-speed imaging of ArchLight-Q239 revealed that U18-treated neurons had similar fluctuations in intensity when compared to U18 and CCAD (Fig. S7B), suggesting that CCAD-dependent decreases in Ca2+ (Fig. 8D) occur through selective uncoupling of KV2.1–CaV1.2 rather than alterations in neuronal excitability.
Taken together, these results demonstrate a role for NPC1 in the downstream organization of spatial and functional coupling between PM KV2.1–CaV1.2 and the ER to regulate ER–PM Ca2+ nanodomains.
Remodeling of ER–PM and ER–Mito MCSs results in neurotoxic increases in mitochondrial Ca2+ and neurodegeneration
Our data suggest there are significant alterations to global and local (ER–PM MCSs) Ca2+ nanodomains in NPC neurons. Considering the importance of appropriately regulated Ca2+ levels for neuronal signaling, we next wanted to determine if these excessive Ca2+ events had toxic consequences for neuronal viability. In neurons, the ER and mitochondria act as major buffers in response to high cytosolic Ca2+ levels. Functional coupling between the IP3R and the Voltage-Dependent Anion channel 1 (VDAC1) at ER–Mito MCSs ensures a steep local Ca2+ gradient for Ca2+ to move into mitochondria to maintain energy production and cell health77,78. However, deviant mitochondrial Ca2+ (Ca2+Mito) levels can lead to altered bioenergetics, ATP production, and Reactive Oxygen Species (ROS) production, triggering necrosis or apoptosis79,80,81. Therefore, we tested the hypothesis that NPC1-dependent elevations in cytoplasmic Ca2+ increases Ca2+Mito and leads to neurotoxicity (Fig. 9A).
We began by characterizing the gross structural organization of the ER and mitochondria in control and U18-treated cells loaded with mitochondria- and ER-permeable dyes. Super-res AiryScan microscopy was performed to measure the overlapping signal near the PM. These analyses demonstrated that the proportion of ER overlapping with mitochondria was very similar in both conditions (Fig. S8A), suggesting that at this resolution there are no obvious rearrangements of these organelle membranes. Next, we asked more specifically if ER–Mito Ca2+ domains were affected by NPC1 function. At ER–Mito MCSs the IP3R and VDAC1 are coupled through interactions with the chaperone protein GRP7582. To determine if the IP3R–GRP75–VDAC1 signaling axis, which has been implicated in the progression of other neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis, undergoes reorganization in NPC disease we took a two-pronged approach leveraging NPC1−/− cells and neurons treated with U18. First, using control and NPC1-/- cells, or vehicle and U18-treated neurons, we immunolabeled for the GRP75 protein and acquired super-resolution AiryScan confocal images. Fig. 9B shows that the total fluorescence intensity, cluster density and cluster size was augmented in U18-treated neurons compared to control. Similarly, NPC1−/− cells also showed higher GPR75 intensity levels and larger clusters (Fig. S8B), indicating enhanced GPR75 at ER–Mito MCSs.
To understand if increased GRP75 cluster size and intensity also reflects remodeling of IP3R and VDAC1 proteins at ER–Mito MCSs we quantified the overlap between these proteins using two models of NPC disease. First, using neurons, we fixed and co-immunolabeled for VDAC1 and IP3R1 before imaging using super-resolution Airyscan confocal microscopy. As shown in Fig. 9C, analyses of resultant 2-color images determined that the proportion, density, and size of VDAC1–IP3R overlapping clusters were all significantly increased in U18 conditions. Similar experiments performed using NPC1−/− cells (Fig. S8C), HEK cells that have endogenous IP3R1 tagged with eGFP (Fig. S8D83), and blinded neuronal experiments (Fig. S8E) revealed that NPC1 knockout or inhibition increased the amount of overlapping IP3R–VDAC1. Taken together, our data indicated that the IP3R–GPR75–VDAC1 signaling axis is upregulated following NPC1 loss-of-function, suggesting Ca2+ flux from ER to mitochondria may be altered in NPC disease.
The remodeling of ER–Mito Ca2+ handling proteins following loss of NPC1 function prompted us to ask if free Ca2+ levels within the ER and mitochondria are also altered in neurons. Previously it has been shown in non-excitable cell models of NPC disease, including cells harboring the most prevalent patient mutation, that loss of NPC1 function results in decreased ER Ca2+ (Ca2+ER) levels due to increased ER Ca2+ leak through IP3R117,23. To test if similar results occur in neurons, we transfected neurons with the ER-targeted GCaMP indicator, GCaMP6-15084, and treated with vehicle control or U18. Aligned with published results, loss of NPC1 function resulted in about a 50 % decrease in GCaMP intensity (Fig. 10A). These data support published data that loss of NPC1 function decreases Ca2+ER.
In NPC disease, decreases in Ca2+ER occur due to enhanced opening of IP3R1 receptors17. Given the enhanced proximity and size of IP3R1–VDAC1 interactions (Fig. 9C), we tested if leaky IP3R1 receptors result in elevated neuronal mitochondrial Ca2+ (Ca2+Mito). To evaluate Ca2+Mito we transfected cortical neurons with a mitochondria-targeted RCaMP plasmid (pCAG-mito-RCaMP1h)85, and incubated neurons with vehicle or U18 for 24 h. Consistent with the model that leaky IP3R1 on ER membranes drive Ca2+ entry into mitochondria, normalized pCAG-mito-RCaMP1h intensities were significantly elevated following the loss of NPC1 function (Fig. 10B). To test a central role for ER Ca2+ stores and IP3R1 in facilitating increases in neuronal Ca2+Mito we treated with vehicle or xestospongin C (XestoC; IP3R inhibitor) and found that U18-dependent elevations in Ca2+Mito were abrogated (Fig. 10B). To further define the upstream source of Ca2+, we treated neurons with vehicle control and nifedipine (L-type CaV1 inhibitor; Nif). Consistent with the model that CaV1 channels play a central role in mediating increases in Ca2+Mito in NPC disease, treatment with nifedipine abolished increases in Ca2+Mito (Fig. 10B). Interestingly, AP blockage by TTX also prevented elevated Ca2+Mito in U18 neurons (Fig. 10A), suggesting that increased neuronal excitability observed in NPC disease leads to elevated Ca2+Mito. Since increased KV2.1–CaV1.2 interactions play a major role in CaV1.2 clustering (Fig. 4) and in localized Ca2+ activity at KV2.1-forming ER–PM MCSs (Fig. 8), we predicted that KV2-dependent interactions with CaV1 may underlie elevations in Ca2+Mito in NPC disease. To test this prediction, we incubated neurons with CCAD to uncouple KV2 from CaV1 and determined that like nifedipine treatment, disengaging KV2 from CaV1 resulted in neuronal Ca2+Mito being refractory to U18 (Fig. 10C). Similar results were observed with roscovitine (Fig. S9B) and place KV2.1–CaV1 interactions at ER–PM MCSs as the most upstream source of Ca2+ driving increases in Ca2+Mito in NPC disease. Alterations in Ca2+Mito are often accompanied by alterations in reactive oxygen species (ROS) and changes in mitochondrial membrane potential (MMP) therefore we tested if they were also altered in models of NPC. Like Ca2+Mito, both ROS and MMP were differentially changed following NPC1 inhibition with levels of ROS increased (Fig. 10D) and MMP less polarized (Fig. 10E). Significantly, treatment of neurons with CCAD rescued defects in ROS and MMP.
Sustained elevations in Ca2+Mito or alterations in ROS and MMP can be detrimental to neuronal health and are frequently triggers for neurodegeneration. Thus, we tested if the mitochondrial phenotypes noted above correlate with changes in neuronal fidelity in NPC disease. As shown in Fig. 10F, viability was significantly decreased following 48 h of NPC1 inhibition. Treatment with XestoC or roscovitine abolished NPC1-driven toxicity (Fig. 10F) emphasizing the important roles IP3R and CDK5 play in decreasing neuron viability. Moreover, uncoupling KV2.1–CaV1.2 interactions through the CCAD peptide completely rescued neurons from toxicity (Fig. 10F).
Collectively, these data suggest that augmented Cav1.2–Kv2.1 interactions at ER–PM MCSs drive deviant increases in Ca2+Mito to promote neurotoxicity in NPC disease.
Discussion
In the present study, we provide evidence linking the NPC1 cholesterol transport to the regulation of ER–PM and ER–Mito Ca2+ signaling nanodomains and neurodegeneration. We show in models of NPC disease that loss of NPC1 cholesterol transporter function facilitates a KV2.1-dependent reorganization of CaV1.2–SERCA–RyR Ca2+ handling proteins to potentiate Ca2+ entry at ER–PM MCSs. In parallel with these changes, we also report the molecular remodeling of the IP3R1–GRP75–VDAC1 Ca2+ complexes at ER–Mito MCSs. Collectively, NPC1-dependent remodeling of these junctions creates a damaging feed-forward Ca2+ signaling axis which drives Ca2+ entry into mitochondria leading to neurotoxicity. Importantly, we show that uncoupling KV2–CaV1 interactions at ER–PM MCSs rescues the NPC1-dependent mitochondrial Ca2+ defects and neurotoxicity, strongly suggesting that Ca2+ entry at upstream ER–PM MCSs is a key driver of Ca2+-dependent neurodegeneration (see Fig. S10 for model).
NPC disease is a neurodegenerative disorder that is characterized by the accumulation of cholesterol within the lysosome. In addition to this cellular phenotype, neurons from several models of NPC disease are hyperexcitable and fire APs at a higher frequency than WT neurons52. A simple prediction was that this hyperexcitability phenotype would increase voltage-dependent Ca2+ entry into NPC neurons. Indeed, we demonstrate that NPC1 loss of function leads to more frequent, electrically driven oscillations in intracellular Ca2+. In addition, we have also discovered that alterations in the nanoscale organization of Ca2+ handling proteins, localized at ER–PM MCSs, further potentiates Ca2+ entry. Central to these structural rearrangements is KV2.1 which influences the distribution and activity of CaV1 channels, RyR, and SERCA2,31,36,75. We find that increased clustering of KV2.1 enhances interactions with CaV1 channels to increase their density and cluster size. This is important as the distribution of CaV1 channels dictates their function with clustered CaV1 channels functionally communicate with one another via their C-termini to mediate their cooperative gating57,58,59,60,61. The opening of CaV1 channels within a cluster is driven by the channel with the highest open probability leading to an overall enhancement in channel activity and resultant amplification of Ca2+ influx. Observations of modified CaV1 channel nanoscale structure–activity relationships have been proposed as key contributors to the disease progression of pathologies such as Timothy syndrome60, hypertension60, and diabetes86, and here we detail similar observations in a neurodegenerative disorder. It is conceivable that similar changes in the nanoscale distribution and activity of CaV1 channels may occur in other neurodegenerative disorders where dysfunctional Ca2+ signaling and altered cholesterol homeostasis have been observed8,9,38,45,87,88,89.
The molecular link between NPC1 and enhanced KV2.1–CaV1 interactions appears to involve the protein kinase CDK5. Phosphorylation of KV2.1 by CDK5 enhances channel clustering67. Furthermore, CDK5 kinase activity is elevated in NPC disease68,90. We find that CDK5 activators, p35/p39 have increased expression in NPC disease and inhibition of CDK5 kinase activity with roscovitine abrogates enhancement of both KV2.1 and CaV1.2 clustering in the PM of NPC neurons. Based on this information, we propose a model wherein loss of NPC function increases CDK5 partitioning to the plasma membrane resulting in a shift in the fractional amount of phosphorylated KV2.1, enhancing its clustering and consequently the distribution and activity of CaV1 channels at the PM. Interestingly, a parallel consequence of increased phosphorylation of KV2.1 would be a decrease in its overall activity as a K+ conducting channel91 which may potentially contribute to the hyperexcitability phenotype in NPC52. Many questions arise from our findings, for example, what is the link between NPC1 and CDK5 activity? We provide evidence that hyperactive mTORC1 activity may be part of the molecular pathway between NPC1 and increased ER–PM Ca2+ activity in NPC but more experiments are required to understand the precise steps that allow such signaling to proceed. Second, with the increases in excitability and Ca2+ entry: why doesn’t calcineurin activity act as a homeostatic counterbalance to CDK5 to ensure KV2.1 clustering at ER–PM contact sites stays in a ‘physiological’ range? Perhaps the depleted lysosomal Ca2+ stores in NPC depress the catalytic activity of calcineurin92,93. We provide evidence that CDK5 and KV2.1 come into closer proximity following NPC1 inhibition which perhaps favors a net increase in KV2.1 phosphorylation and consequently KV2.1–CaV1 complex formation. Future analyses should begin targeting these key questions to unmask and define the complete molecular cascade that exists between NPC1 cholesterol efflux and the tuning of ion channel distribution at ER–PM MCSs.
In addition to physically interacting to organize CaV1 channels, KV2 also functionally coordinates RyR and SERCA at ER–PM nanodomains2,31,35. We find that loss of NPC1 function positively remodels the distribution of these proteins at ER–PM MCSs to increase Ca2+ entry into the cytoplasm. It is noteworthy that as KV2.1 cluster size and density increase so does the number of ER–PM MCSs. This observation aligns with reports that phosphorylated KV2.1 interacts with the ER VAP proteins to generate ER–PM MCSs34,35. However, our data suggest that it is not simply the physical coupling of KV2.1–VAP that defines this sub-population of ER–PM MCSs, as uncoupling CaV1 from KV2 channels with CCAD, a perturbation that maintains KV2.1–VAP interactions2, decreases the overall number and density of ER–PM MCSs. That uncoupling of KV2–CaV1 channels reduces the amount of Ca2+ entry into the cytoplasm (Fig. 8C and ref. 2) supports that KV2–CaV1 dependent Ca2+ entry is either a stimulus for stabilizing ER–PM MCS or an instructive signal to induce the formation of new ER–PM MCSs in neurons. The latter model that Kv2–CaV1 Ca2+ entry nucleates the formation of new MCSs aligns with previous reports that a number of lipid binding ER–PM MCS forming proteins are sensitive to local changes in cytoplasmic Ca2+ concentrations29,94 and provides evidence that KV2 channels are a crucial foundational element that regulates multiple sub-populations of ER–PM MCSs.
In the present study, we find that NPC1 deficiency leads to increased proximity between CaV1.2–RyR and KV2.1–SERCA, suggesting that KV2.1-associated ER–PM MCSs are enriched in RyR, SERCA and CaV1.2, consistent with previous proteomics analyses of Kv2.1-containing ER-PM MCSs purified from mouse brain31. Having more CaV1.2 juxtaposed to RyR would amplify Ca2+ entry into the cytoplasm through Ca2+-Induced Ca2+-Release (CICR). Such amplification of Ca2+ signals is important in normal neuronal function as it facilitates excitation-transcription coupling2, however, in NPC disease it is further increased and together with the hyperexcitability phenotype results in aberrant and ultimately neurotoxic (see below) increases in Ca2+. An intuitive prediction of enhanced KV2–CaV1–RyR Ca2+ entry in NPC disease would be an increase in ER Ca2+ levels. The statement is supported by the increase in clustering at ER–PM MCSs of two ER Ca2+ uptake mediator proteins, KV2.1 and SERCA (Fig. 3 and S7A)75, and increased SERCA activity in NPC disease models23. Thus, it was initially surprising that despite the alignment of these factors, ER Ca2+ levels are significantly decreased in NPC disease (Fig. 10A and ref. 23). The molecular mechanism underlying reduced ER Ca2+ in NPC disease is enhanced spontaneous Ca2+ release from IP3R1 in ER membranes17. Evidence herein suggests that heightened RyR CICR activity may also contribute to the leaky ER Ca2+ phenotype in NPC disease.
A common feature in neurodegenerative disorders is mitochondrial Ca2+ overload leading to mitochondrial membrane rupture and release of pro-apoptotic factors17,77,95,96,97,98. The IP3R–GRP75–VDAC1 signaling axis is a hotspot for Ca2+ flux from the ER towards the mitochondria. Our data provide evidence that ER Ca2+ stores are low whereas mitochondrial Ca2+ is significantly increased in NPC neurons. Furthermore, we find that increases in mitochondrial Ca2+ correlate with alterations in MMP, increased ROS generation, and cell death supporting the model that mitochondrial Ca2+ overload is a mechanism for neurodegeneration in NPC disease. Mechanistically, increased interactions between IP3R–GRP75–VDAC1 at ER–Mito MCSs coupled with more spontaneously active IP3R117 creates the opportunity for destructive funneling of Ca2+ into mitochondria. We propose that in NPC disease, excess KV2–CaV1 Ca2+ entry at ER–PM MCSs is transported into the ER through increased SERCA activity23 and clustering but instead of accumulating to increase ER Ca2+ concentrations, is quickly released by IP3R1 receptors at ER–Mito MCSs to promote neurotoxic increases in mitochondrial Ca2+ (Fig. S10). Supporting this model, we demonstrate that disrupting KV2–CaV1 interaction or reducing CDK5 phosphorylation of KV2 channels reduces mitochondrial Ca2+ levels and rescues neuronal death following NPC1 inhibition, supporting the concept that KV2–CaV1 Ca2+ entry at ER–PM MCSs is an upstream contributing factor to neurotoxic increases in mitochondrial Ca2+ in NPC. Future investigations should lead to a better understanding of whether disrupting Ca2+ entry at KV2–CaV1 nanodomains has beneficial effects on disease progression in NPC disease models, as it does for stroke models66,99. Noteworthy, previous reports have linked altered KV2.1 activity to cell death through increased K+ efflux activating pro-apoptotic pathways100,101 rather than by favoring Ca2+ entry as we describe for NPC disease. Together, these data reinforce the need for homeostatic control of conducting (K+ efflux) and non-conducting (Ca2+ nanodomain organization) KV2.1 subpopulations by protein kinases and phosphatases to ensure the maintenance of neuronal health.
Why is there such a prominent Ca2+ phenotype across multiple organelles in NPC disease? Our working model is that alterations in Ca2+ gradients across MCSs represent cellular programs attempting to redistribute cholesterol rapidly and efficiently to cellular membranes to restore cholesterol homeostasis93,102,103. In this model, unless new homeostatic set points are found quickly, gross alterations in Ca2+ gradients, as well as lipids16,52, provide a substrate for neurodegeneration17,23. To design rational targets to slow or abrogate NPC-linked pathology, further quantitative characterization of the structural and functional alterations to ER–PM contacts and the downstream consequences linking mitochondrial Ca2+ elevations to neurodegeneration are required.
To conclude, this study details a molecular link between cholesterol egress from lysosomes and the reorganization of Ca2+ handling proteins at two membrane contact sites: ER–PM and ER–Mito. Our data demonstrate that NPC is a nanostructural ion channel clustering disease with altered ion channel distribution/activity at membrane contacts contributing to neurodegeneration.
Methods
Key resources
Key resources are documented in Supplementary Table 1.
Animals
All experiments were performed in strict compliance with the University of California Davis ethical regulations for studies involving animals as approved by the University of California Davis Animal Care and Use Committee (protocol #: 22644). C57BL/6 WT and NPC1I1061T mice were purchased from The Jackson Laboratory and kindly provided by Daniel Ory64, respectively. Mice were maintained under standard light-dark cycles, fed standard chow and water ad libitum, and housed in a vivarium with controlled conditions.
Cell culture
tsA201 cells were purchased from Sigma (Cat #96121229), CHO WT and NPC1−/− cells were a kind gift from Dr. Ory (Washington University, St. Louis, MO), HeLa WT and NPC1−/− cells were a kind gift from Dr. Judith Storch (Rutgers). tsA201 and HeLa cells were cultured in DMEM supplemented with 10% FBS (GIBCO, Cat #26140-079), with 2 mM L-glutamine (GIBCO, Cat #25030-081) and 0.2% Penicillin/Streptomycin (GIBCO, Cat #15140-122). CHO cells were cultured in DMEM/F12 (1:1) (GIBCO, Cat #11320033) supplemented with 10% FBS (GIBCO, Cat #26140-079) and 0.2% Penicillin/Streptomycin (GIBCO, Cat #15140-122). All cell lines were passaged twice weekly and incubated in 5% CO2 at 37 °C. NPC1−/−
Cortical neurons from mice of both sexes were dissociated at embryonic day 15–18 (E15–18) using the Papain Dissociation System purchased from Worthington (Cat #LK003150). All stock solutions were prepared as per manufacturer’s recommendations. Dissection was conducted in sterile PBS at 4 °C as previously described in104 and meninges, cerebellum, hippocampus, and striatum were discarded. Cortical tissue was pelleted and incubated in papain for 20 min at 37 °C (agitating every 5 mins), followed by trituration. Consequently, cells were centrifuged 5′ at 1000g and resuspended in Earle’s Balanced Salt Solution (EBSS), ovomucoid (papain inhibitor) and DNase. Neurons were plated in Neurobasal (21103-049; Gibco) supplemented with B27 (GIBCO, Cat #17504-044), Glutamax (GIBCO, Cat #35050-061) and 0.2% penicillin/streptomycin at a density of 650,000 cells / mL. Neurons were incubated in 5% CO2 at 37 °C and half of the media was changed every 4 days. Experiments were performed at DIV 6-8, except for the GCaMP3-Kv2.1P404W Ca2+ imaging which was conducted at DIV 14–16. Rat cortical neurons were dissected and isolated at gestation day 18 as previously described in Vierra et al.31.
Reagents
Xestospongin C (XestoC) was dissolved in DMSO and used at a final concentration of 10 µM and incubated overnight (O/N) or for 48 h. Torin-1 was dissolved in DMSO and used at a final concentration of 10 µM and incubated O/N. U18666A (U18) was dissolved in DMSO to a final concentration of 10 µM and incubated O/N or for 48 h. Tetrodotoxin (TTX) was dissolved in DMSO and incubated O/N at a final concentration of 200 nM. roscovitine (Rosc) was dissolved in DMSO and incubated O/N or for 48 h at a final concentration 10 µM. Ionomycin was dissolved in DMSO and used at a final concentration of 2.5 µM for ∼6 min. TAT-FFAT-HA (472-481) (FFAT), TAT-HA-C1aB (CCAD) and their respective control scramble peptides TAT-HA-C1aB-Scr and TAT-FFAT-HA (472-481)-Scr (SCBRL) were dissolved in molecular biology grade water and used at a final concentration of 1 µM for 48 h.
Fillipin staining
Cells were washed with PBS and fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Cat #15710) for 20 min at 21 °C. Cells were stained with fillipin (100 µg/ml in PBS) for 2 h at room temperature (RT, 21–23 °C). During the fillipin staining process cells were protected from light exposure. Cells were excited using a 405-nm LED and light collected using a Plan-Apochromat 63×/1.40 oil-immersion lens and a Zeiss LSM 880 Airyscan microscope. Images were acquired in PBS solution at RT using Zen v2.3 software.
Protein extraction and abundance determination
Protein was harvested from neuronal cultures in RIPA buffer (Thermo Scientific, Cat #89900) containing Complete/Mini/EDTA-free protease inhibitor cocktail (Roche, Cat #11836170001), sodium fluoride 1 mM (Sigma-Aldrich, Cat #67414), SDS 0.05%, sodium deoxycholate 0.4% (DOC) and Microcystin 4 µg/mL (Sigma Millipore, Cat #475821). Cells were scraped in 100 μL of lysis buffer and centrifuged at 13,200 rpm for 20 min at 4 °C to isolate the postnuclear supernatant. Protein concentration was quantified using a Pierce BCA protein assay kit (Thermo Scientific, Cat #23225). 15 μg of each protein sample was added to 4%–12% Bis-Tris gels and electrophoresed under reducing conditions for approximately 75 min at 155 V. Proteins were transferred onto nitrocellulose membranes (Life Technologies, Cat #LC2000) using the Mini-Blot system (Thermo Scientific, Cat #A25977) for 2 h 30 min at 12 V (∼200 mA). After 30 min incubation at RT in Tris-Buffered Saline (TBS) buffer supplemented with 0.05% Tween‐20 (TBS-T) and 5% non‐fat dry milk, membranes were exposed O/N at 4 °C to the following primary antibodies: KV2.1 at 4 μg/mL (NeuroMab, K89/34), CaV1.2 at 1:250 (Alomone Labs, acc-003), CDK5 at 1:100 (Santa Cruz Biotechnology, Cat #sc-6247), p35 at 1:100 (Cell Signaling Technology, Cat #C64B10), p39 at 1:100 (Santa Cruz Biotechnology, Cat #sc-365781) or GAPDH at 1:1000 (Proteintech, Cat #10494-I-AP). Blot bands were detected using fluorescent secondary antibodies goat anti-rabbit 680RD at 1:1000 (LI-COR, Cat #P/N 926-68071) and goat anti-Mouse 800CW at 1:1000 (LI-COR, Cat #P/N 925-32210). Signals were detected using Azure SapphireTM Biomolecular Imager (Azure Biosystems) and quantified using the ImageJ software. Abundance of proteins was normalized to GAPDH.
Transfection and plasmids
Plasmid transfection mixtures were prepared using 2.5 µl/ µg DNA of Lipofectamine 2000 (Invitrogen, Cat #11668-019), added to neurons and incubated for 2 days. The following plasmids (per 650,000 neurons) were used in this study: 4 µg pCAG-mito-RCaMP1h (Addgene, Cat #105013), 4 µg ER-GCaMP6-150 (Addgene, Cat #86918), 2 ug ArcLight-Q239 (Addgene, Cat #36856)76, 2 µg GFP-MAPPER74, 1 µg SPLICSL-P2AER-PM (Addgene, Cat #164111), 1 µg SPLICSS-P2AER-PM (Addgene, Cat #164112) and 1.1 µg GCaMP3-Kv2.1P4O4W31. Plasmid transfection mixtures for CHO cells were prepared using 7 µl of Lipofectamine LTX and 7 µl of Plus (Invitrogen, Cat #15338-030) and were imaged the day after transfection. The following plasmids were used: 1 µg per 960,000 cells rat CaV1.2α1c (GenBank number NP_001129994.1; a gift from Dr. William Catterall, University of Washington, Seattle, WA), 1 µg per 960,000 cells rat CaVα2δ (AF286488; a gift from Dr. Diane Lipscombe, Brown University, Providence, RI), 1 µg per 960,000 cells CaVβ3 (M88751; a gift from Dr. Diane Lipscombe, Brown University, Providence, RI) and 1 µg per 960,000 cells DsRed-KV2.135.
Super resolution airyscan imaging
Imaging was conducted at RT using a Zeiss LSM880 confocal laser scanning microscope equipped with a Plan‐Apochromat 63× 1.4 Oil DIC M27 objective and a super‐resolution Airyscan detection unit. Images of GFP/Alexa‐488, Alexa-568/mCherry and Alexa‐647 were collected using 488-, 594- and 633-nm excitation lasers, respectively, with multicolor images sequentially acquired. Fixed and live cells were acquired in PBS or Ringer’s solution (in mM, 160 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 8 D‐Glucose) with the ZEN software v2.3, respectively. Images were taken at 0.5 μm depth intervals within the cell (see PLA assay and ER staining in live neurons) or as a single internal or plasma membrane plane for HA, GRP75, IP3R and VDAC1, or, CaV1.2, CaV1.3, KV2.1, CaV2.1 and RyR immunolabeling, respectively. 3D analysis for the ER morphology in neurons was conducted with the IMARIS software (Oxford Instruments); all other datasets were carried out following background subtraction and similar thresholding using ImageJ (NIH, Bethesda, MD, USA). Colocalization/overlap analyses were performed by multiplying binary masks of CaV1.2, KV2.1, RyR, IP3R, VDAC1, ER and mitochondria images. For neuronal analyses, the soma area and a 15 µm2 ROI from proximal neuronal dendrites were used. For protein clustering and ER–PM MAPPER puncta studies in the soma and cell body, sum intensity and numbers of clusters were normalized to their respective areas.
Super resolution TIRF imaging
Images were acquired using a Leica Infinity TIRF microscope equipped with a 163× 1.49 (fixed cells) and a 100× 1.47 (live cells) CORR TIRF oil immersion objective and a Hamamatsu orca flash 4.0 camera. Leica LAS X software was employed for both image acquisition and processing. GFP/YFP, Alexa‐647 and Alexa-568 images were collected with the 488 nm, 638 nm and 561 nm excitation lines, respectively. Fixed or live cells were imaged in a GLOX–MEA (Tris 10 mM pH8, Glucose Oxidase 56 mg/mL, Catalase 34 mg/mL, 10 mM MEA) or Ringer’s solution (in mM, 160 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 8 D‐Glucose), respectively. For fixed cell imaging (KV2.1–VAPA/B, KV2.1–CDK5, CaV1.2, KV2.1, KV2.1–CaV1.2 and KV2.1–SERCA) 50,000 cycles with an exposure time of 10 ms were acquired and imaging analysis was performed using IMARIS software (Oxford Instruments). For all analyses, cluster number was normalized to the respective soma area. Colocalization/overlapping analyses were performed by creating a 2D KV2.1 mask and measuring CaV1.2, CDK5, VAPA/B or SERCA areas within said mask. Live cell imaging of GCaMP3-KV2.1P4O4W analyses were performed using the ImageJ and ClampFit (Molecular Devices) softwares.
Immunofluorescence immunocytochemistry
Antibody dilutions/amounts, validation, company names, catalogue numbers and clone numbers can be found either below, in the reporting summary, and/or supplementary table 1. Cells were fixed for 20 min at RT in PBS with 4% formaldehyde freshly prepared from paraformaldehyde and blocked for 1 h in 50% SEA BLOCK and 0.5% Triton X‐100 solution. Neurons were incubated O/N at 4 °C in 20% SEA BLOCK and 0.5% Triton X‐100 in PBS with the following primary antibodies: GRP75 1:100 (Abcam, Cat #ab2799), KV2.1 10 µg/mL (NeuroMab, K89/34), CaV1.2 1:333 (Alomone, Cat #acc-003), KV2.1(pS603) 1:5 (L61/14.2), VDAC1 1:100 (Abcam, Cat #ab14734), SERCA 10 µg/mL (Abcam, Cat #ab2861), CaV1.3 10 µg/mL (Alomone Labs, Cat #ACC-005), pan-RyR 1:100 (Abcam, Cat #ab2868), IP3R 18 µg/mL (Abcam, Cat #ab5804), CaV2.1 1:200 (Alomone Labs, Cat #ACC-001), and KV2.1 pS603 1:5 (L61/14). After primary antibody incubation, neurons were washed 3 × 5 min and subsequently incubated for 1 h at RT with the following secondary antibodies: Goat anti-Mouse-647 and −568 nm 1:1000 (Invitrogen, Cat #A21236 and Cat #A11031, respectively), anti-Rabbit-647 and −555 nm 1:1000 (Invitrogen, Cat #A21245 and Cat #A21429, respectively), anti-Mouse IgG1-568 nm 1:1000 (Invitrogen, Cat #A21124) and anti-Mouse IgG1-CF568 1:250 (Sigma-Aldrich, Cat #SAB4600314).
Immunofluorescent labeling of brain sections
Fixation: Postnatal day 60 (P60) wild-type and NPC1I1016T mice were anesthetized and transcardially perfused with 4% phosphate buffered (PB) formaldehyde (pH 7.4) made from powdered paraformaldehyde using a peristaltic pump. Perfused brains were collected and cryoprotected with 30% sucrose/PB solution. Sectioning: Sagittal brains sections (30 µM) were generated using a freezing microtome and immunolabeling was performed on free floating sections. Briefly, tissue was blocked in 10% normal goat serum (NGS) with 0.3% TritonX-100 in 0.1 M PB at RT for 1 h followed by incubation in primary antibody O/N at 4 °C. Primary antibody incubation was performed in 5% NGS/0.3% TritinX-100/0.1 M PB. Antibodies: the following primary antibodies were used for immunolabeling: Calbindin 1:200 (Sigma-Aldrich #C9848),Calbindin, 2 µg/mL (L109/57, NeuroMab), KV2.1 10 µg/mL (NeuroMab, K89/34), CaV1.2 1:200 (Alomone Labs, Cat #acc-003), CaV1.2 5 µg/mL (NeuroMab, N263/31 R). Species-specific Alexa Fluor 488, 555 and 647conjugated secondary antibodies (2 µg/mL; Life Technologies) were incubated for 60 min at RT. Images were taken using a Zeiss ApoTome Fluoview FV3000 confocal microscope (Olympus) or a Zeiss Axioscope 2 widefield microscope with ApoTome. All images were assembled using FIJI and Illustrator (Adobe). CaV1.2–KV2.1 colocalization volumes were calculated using IMARIS software by quantifying the KV2.1-positive pixels inside a 3D CaV1.2 mask.
PLA assay
The Duolink In Situ PLA kit (Sigma-Aldrich, Cat #DUO92004-100RXN and DUO92002-100RXN) was used to quantify CaV1.2-KV2.1 proximity in fixed cortical neurons treated with U18 or vehicle control (DMSO). Following fixation, as described in Immunofluorescence Immunocytochemistry above, cells were incubated for 15 min with 100 mM glycine at RT. Subsequently, neurons were washed in PBS (2 ×3 min) and permeabilized in 0.1% Triton-X100 for 20’ at RT. Neurons were blocked in a 20% SEA BLOCK solution (Thermo Scientific, Cat #37527) for 1 h and incubated at 4 ̊C O/N with the following primary antibodies: KV2.1 10 µg/mL (NeuroMab, K89/34) and CaV1.2 1:333 (Alomone, Cat #acc-003;1:333). Secondary oligonucleotide-conjugated antibodies (PLA probes: anti-mouse MINUS and anti-rabbit PLUS) were used at 1:5 dilution in Duolink Antibody Diluent. PLA assay was performed as per the manufacturer’s recommendations. Coverslips were mounted with DAPI Fluoromount-G (SouthernBiotech, Cat #0100-20). The fluorescence signal was detected using a Zeiss LSM880 confocal laser scanning microscope equipped with a Plan‐Apochromat 63× 1.4 Oil DIC M27 objective and a super‐resolution Airyscan detection unit. 405- and 488-nm lasers were employed to visualize the DAPI-stained nucleus and PLA signal, respectively. For each neuron, optical z-axis sections were acquired at 0.5 μm intervals and combined to a single maximum intensity projection using ImageJ.
ER and mitochondrial staining in live neurons and tsA201 cells
Cells were incubated for 20 min using Mito Tracker (50 nM; Invitrogen, Cat #M22426) and ER Tracker (100 nM; Invitrogen, Cat #E12353). Cells were subsequently washed twice (5 min each time) before being imaged with a Zeiss LSM880 confocal laser scanning microscope equipped with a Plan‐Apochromat 63× 1.4 Oil DIC M27 objective and a super‐resolution Airyscan detection unit; 633- and 546-nm excitation lasers were used to image mitochondria and ER, respectively. For tSA201, cells single planes near the PM were acquired and overlapping areas between both organelles were analyzed by multiplying their respective binary masks in ImageJ and normalized to the respective cell body area. For neurons, z-stacks were taken at 0.5 μm depth intervals within the cell and analysis was performed in the IMARIS software (Oxford instruments).
Mitochondrial and ER Ca2+ imaging
48 h post-transfection with pCAG-mito-RCamPh1 or ER-GCaMP6-150, neurons were imaged in a 2 mM Ca2+ Ringer’s solution using a LSM880 confocal laser scanning microscope equipped with a Plan‐Apochromat 63× 1.4 Oil DIC M27 objective and a super‐resolution Airyscan detection unit. A 546 nm laser was used to excite pCAG-mito-RCamPh1, while a 488 nm laser was used to excite ER-GCaMP6-150. After collection of a baseline image, cells were perfused with a 20 mM Ringer’s solution containing 2.5 µM Ionomycin for 6 min. The mean intensity ratio of pre-ionomycin/post-ionomycin signals was calculated for each cell. Higher ratios were taken to indicate higher resting mitochondrial or ER Ca2+ concentrations.
Cytosolic Ca2+ imaging
Cells were incubated in a 2 mM Ca2+ Ringer’s solution containing 2.5 µM Fluo-4 and 0.1% Pluronic acid for 30 min. Cells were then moved to a Fluo-4–free Ringer’s solution to deesterify the Fluo-4 for 30 min. Following deesterification, Fluo-4–loaded cells were excited with a 488-nm laser and the resulting fluorescence monitored using an inverted microscope with a Plan-Apochromat 63×/1.40 oil objective, connected to an Andor W1 spinning-disk confocal with a Photometrics Prime 95B camera. Images were acquired every 50 ms for a total of 50 s in a 2 mM Ca2+ Ringer’s solution at RT using Micromanager (1.4.21) software. Electrical stimulation at 40 V was performed at 1 Hz for 5 s with a Field Stimulator (IonOptix). Intracellular Ca2+ activity was measured as Ca2+ peak frequency and Ca2+ peak amplitude in a Region of Interest (ROI) localized in the soma or proximal neuronal dendrites using ImageJ or ClamPfit software.
GCaMP3-Kv2.1P4O4W imaging
48 h post-transfection, TIRF imaging was performed using a Leica Infinity TIRF super-resolution microscope equipped with a 100× 1.47 TIRF oil immersion objective and a Hamamatsu Orca Flash 4.0 camera. Images were acquired in Ringer’s solution (in mM, 160 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 8 D‐Glucose) containing B-Kay 500 nM every 100 ms for a total time of 50–100 s by exciting with a 488-nm laser. Ca2+ activity was measured as GCaMP3-Kv2.1P4O4W peak amplitude in a ROI localized in the soma or proximal neuronal projections using ImageJ and ClamPfit softwares.
H2DCFDA assay (ROS production)
The ROS production assay was conducted as per the manufacturer’s recommendations (Invitrogen, Cat #D399). Live DIV 6-8 cortical neurons were incubated O/N with U18 and CCAD or SCRBL peptides. Single-plane images were collected in Ringer’s solution (in mM, 160 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 8 D‐Glucose) at 488 nm using a Plan‐Apochromat 63× 1.4 Oil DIC M27 objective and a Zeiss 880 Airyscan microscope at RT. Images were analyzed using ImageJ and mean intensities were taken to plot ROS production.
MitoProbe JC-1 assay (mitochondrial membrane potential)
Mitochondrial membrane potential was conducted as per the manufacturer’s recommendations (Abcam, Cat #ab113850) and plotted as a ratio of aggregated JC-1 form/monomer JC-1 form, with higher ratios indicating more polarized membranes. JC-1 aggregates were imaged at a 618 nm emission and a 488 nm excitation, and JC-1 monomers at a 536 nm emission and 488 nm excitation in Ringer’s solution (in mM, 160 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 8 D‐Glucose) using a Plan‐Apochromat 63× 1.4 Oil DIC M27 objective and a Zeiss 880 Airyscan microscope at RT. Images were analyzed using ImageJ software.
Cell viability assay
The cell viability assay was conducted as per the manufacturer’s recommendations (K502-100; BioVision). Live DIV 6–8 cortical neurons were incubated 48 h with U18, XestoC, Rosc or CCAD or SCRBL peptides before being washed once with 2 mM Ca2+ Ringer’s solution and loaded with 1 mL assay buffer containing 2 µL Live cell staining dye and 1 µL Dead cell staining dye. Cells were immediately excited using a 488- and 564- nm LED. Single-plane images were collected using a Plan‐Apochromat 63× 1.4 Oil DIC M27 objective and a Zeiss 880 Airyscan microscope at RT. Images were analyzed using ImageJ. The ratio of live (488 nm) to dead (564 nm) was taken for each single neuron every captured image, with higher ratios indicating increased neuronal viability.
Statistics and reproducibility
The number of replicates is based on previously published observations to reached statistical differences between datasets16,17,23,26,52,104,105,106,107. When comparing two or three independent groups, normality was determined with the Agostino-Pearson omnibus test and a parametric, unpaired t test, or nonparametric, Mann–Whitney t test, was employed. When comparing the means of 4 groups with two or more categorical independent variables, the two-way ANOVA for multiple comparisons with appropriate post hoc test was used. When quantifying fold changes respective to the control condition, one sample t test was employed. P < 0.05 was considered statistically significant (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.001); # shows significance between sample groups and the negative control when ANOVA was employed. To determine whether values within a dataset have significant outliers, a two‐sided Grubbs’ test, with an alpha value of 0.05 was performed. All the data values are presented as means ± SEM and the number of technical and biological replicates is detailed in each figure legend, which is based on previously published observations and is consistent with the general number of replicates and conditions commonly accepted in the field. For each neuronal dataset experiments were performed from 1-4 independent neuronal cultures with each isolation containing 6–8 pups. Several key datasets were blinded and outcome accessed.
Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
Data availability
The data supporting the findings of this work can be found in the source data file and additional raw data will be made available upon request. Source data are provided with this paper.
References
Dietschy, J. M. & Turley, S. D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12, 105–112 (2001).
Vierra, N. C., O’Dwyer, S. C., Matsumoto, C., Santana, L. F. & Trimmer, J. S. Regulation of neuronal excitation-transcription coupling by Kv2.1-induced clustering of somatic L-type Ca2+ channels at ER-PM junctions. Proc. Natl Acad. Sci. USA 118, e2110094118 (2021).
Luo, J., Yang, H. & Song, B.-L. Mechanisms and regulation of cholesterol homeostasis. Nat. Rev. Mol. Cell Biol. 21, 225–245 (2020).
Levitan, I., Fang, Y., Rosenhouse-Dantsker, A. & Romanenko, V. Cholesterol and ion channels. Sub-cellular Biochem. 51, 509–549 (2010).
Ikonen, E. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol. Rev. 86, 1237–1261 (2006).
Maxfield, F. R. & Tabas, I. Role of cholesterol and lipid organization in disease. Nature 438, 612–621 (2005).
Yeagle, P. L. Cholesterol and the cell membrane. Biochim. Biophys. Acta 822, 267–287 (1985).
Leoni, V. & Caccia, C. The impairment of cholesterol metabolism in Huntington disease. Biochim. Biophys. Acta 1851, 1095–1105 (2015).
Vance, J. E. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis. Models Mech. 5, 746–755 (2012).
Pfrieger, F. W. & Ungerer, N. Cholesterol metabolism in neurons and astrocytes. Prog. Lipid Res. 50, 357–371 (2011).
Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47 (1986).
Ikonen, E. & Zhou, X. Cholesterol transport between cellular membranes: a balancing act between interconnected lipid fluxes. Dev. Cell 56, 1430–1436 (2021).
Pfisterer, S. G., Peranen, J. & Ikonen, E. LDL-cholesterol transport to the endoplasmic reticulum: current concepts. Curr. Opin. Lipidol. 27, 282–287 (2016).
Lim, C.-Y. et al. ER–lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signalling in Niemann–Pick type C. Nat. Cell Biol. 21, 1206–1218 (2019).
Castellano, B. M. et al. Lysosomal cholesterol activates mTORC1 via an SLC38A9–Niemann-Pick C1 signaling complex. Science 355, 1306–1311 (2017).
Kutchukian, C. et al. NPC1 regulates the distribution of phosphatidylinositol 4-kinases at Golgi and lysosomal membranes. EMBO J. 40, e105990 (2021).
Tiscione, S. A. et al. IP(3)R-driven increases in mitochondrial Ca(2+) promote neuronal death in NPC disease. Proc. Natl Acad. Sci. USA 118, e2110629118 (2021).
Phillips, M. J. & Voeltz, G. K. Structure and function of ER membrane contact sites with other organelles. Nat. Rev. Mol. Cell Biol. 17, 69–82 (2016).
Voeltz, G. K. & Barr, F. A. Cell organelles. Curr. Opin. Cell Biol. 25, 403–405 (2013).
Toulmay, A. & Prinz, W. A. Lipid transfer and signaling at organelle contact sites: the tip of the iceberg. Curr. Opin. Cell Biol. 23, 458–463 (2011).
Prinz, W. A. Lipid trafficking sans vesicles: where, why, how? Cell 143, 870–874 (2010).
Dixon, R. E. & Trimmer, J. S. Endoplasmic reticulum-plasma membrane junctions as sites of depolarization-induced Ca(2+) signaling in excitable cells. Annu. Rev. Physiol. 85, 217–243 (2023).
Tiscione, S. A. et al. Disease-associated mutations in Niemann-Pick type C1 alter ER calcium signaling and neuronal plasticity. J. Cell Biol. 218, 4141–4156 (2019).
Höglinger, D. et al. NPC1 regulates ER contacts with endocytic organelles to mediate cholesterol egress. Nat. Commun. 10, 4276 (2019).
Yeagle, P. L. Modulation of membrane function by cholesterol. Biochimie 73, 1303–1310 (1991).
Kirmiz, M., Gillies, T. E., Dickson, E. J. & Trimmer, J. S. Neuronal ER-plasma membrane junctions organized by Kv2-VAP pairing recruit Nir proteins and affect phosphoinositide homeostasis. J. Biol. Chem. 294, 17735–17757 (2019).
Dickson, E. J., Jensen, J. B. & Hille, B. Regulation of calcium and phosphoinositides at endoplasmic reticulum-membrane junctions. Biochem. Soc. Trans. 44, 467–473 (2016).
Dickson, E. J., Jensen, J. B. & Hille, B. Dynamic contacts between the endoplasmic reticulum and the plasma membrane regulate phosphoinositide metabolism and control cellular excitability. Biophys. J. 110, 576A (2016).
Sun, E. W. et al. Lipid transporter TMEM24/C2CD2L is a Ca(2+)-regulated component of ER-plasma membrane contacts in mammalian neurons. Proc. Natl Acad. Sci. USA 116, 5775–5784 (2019).
Wu, Y. et al. Contacts between the endoplasmic reticulum and other membranes in neurons. Proc. Natl Acad. Sci. 114, E4859–E4867 (2017).
Vierra, N. C., Kirmiz, M., van der List, D., Santana, L. F. & Trimmer, J. S. Kv2.1 mediates spatial and functional coupling of L-type calcium channels and ryanodine receptors in mammalian neurons. Elife 8, e49953 (2019).
Misonou, H. et al. Regulation of ion channel localization and phosphorylation by neuronal activity. Nat. Neurosci. 7, 711–718 (2004).
Malin, S. A. & Nerbonne, J. M. Delayed rectifier K+ currents, IK, are encoded by Kv2 α-subunits and regulate tonic firing in mammalian sympathetic neurons. J. Neurosci. 22, 10094–10105 (2002).
Johnson, B. et al. Kv2 potassium channels form endoplasmic reticulum/plasma membrane junctions via interaction with VAPA and VAPB. Proc. Natl Acad. Sci. 115, E7331–E7340 (2018).
Kirmiz, M., Vierra, N. C., Palacio, S. & Trimmer, J. S. Identification of VAPA and VAPB as Kv2 channel-interacting proteins defining endoplasmic reticulum-plasma membrane junctions in mammalian brain neurons. J Neurosci 38, 7562–7584 (2018).
O’Dwyer, S. C. et al. Kv2.1 channels play opposing roles in regulating membrane potential, Ca(2+) channel function, and myogenic tone in arterial smooth muscle. Proc. Natl Acad. Sci. USA 117, 3858–3866 (2020).
Simms, B. A. & Zamponi, G. W. Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron 82, 24–45 (2014).
Hurley, M. J., Brandon, B., Gentleman, S. M. & Dexter, D. T. Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain: J. Neurol. 136, 2077–2097 (2013).
Miranda, A. S. et al. Alterations of calcium channels in a mouse model of Huntington’s disease and neuroprotection by blockage of Ca(V)1 Channels. ASN Neuro 11, 1759091419856811 (2019).
Yagami, T., Kohma, H. & Yamamoto, Y. L-type voltage-dependent calcium channels as therapeutic targets for neurodegenerative diseases. Curr. Med. Chem. 19, 4816–4827 (2012).
Ilijic, E., Guzman, J. N. & Surmeier, D. J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol. Dis. 43, 364–371 (2011).
Ritz, B. et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67, 600–606 (2010).
Ghosh, A. & Greenberg, M. Calcium signaling in neurons: molecular mechanisms and cellular consequences. Science 268, 239–247 (1995).
Augustine, G. J., Santamaria, F. & Tanaka, K. Local calcium signaling in neurons. Neuron 40, 331–346 (2003).
Berridge, M. J. Calcium hypothesis of Alzheimer’s disease. Pflugers Arch. 459, 441–449 (2010).
Surmeier, D. J., Guzman, J. N. & Sanchez-Padilla, J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson’s disease. Cell Calcium 47, 175–182 (2010).
Bezprozvanny, I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 15, 89–100 (2009).
Chan, C. S., Gertler, T. S. & Surmeier, D. J. Calcium homeostasis, selective vulnerability and Parkinson’s disease. Trends Neurosci. 32, 249–256 (2009).
Adamczyk, A. & Strosznajder, J. B. Alpha-synuclein potentiates Ca2+ influx through voltage-dependent Ca2+ channels. Neuroreport 17, 1883–1886 (2006).
Stutzmann, G. E., Caccamo, A., LaFerla, F. M. & Parker, I. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer’s-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci. 24, 508–513 (2004).
Smith, R. G. et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. New Engl. J. Med. 327, 1721–1728 (1992).
Vivas, O., Tiscione, S. A., Dixon, R. E., Ory, D. S. & Dickson, E. J. Niemann-Pick Type C disease reveals a link between lysosomal cholesterol and PtdIns(4,5)P2 that regulates neuronal excitability. Cell Rep. 27, 2636–2648.e2634 (2019).
Catterall, W. A. Structure and regulation of voltage-gated Ca2+ channels. Annu. Rev. Cell Dev. Biol. 16, 521–555 (2000).
Schmitt, M., Dehay, B., Bezard, E. & Garcia-Ladona, F. J. U18666A, an activator of sterol regulatory element binding protein (SREBP) pathway modulates presynaptic dopaminergic phenotype of SH-SY5Y neuroblastoma cells. Synapse (New York, N.Y.), 71, https://doi.org/10.1002/syn.21980 (2017).
Lu, F. et al. Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection. eLife 4, e12177 (2015).
Dixon, R. E., Navedo, M. F., Binder, M. D. & Santana, L. F. Mechanisms and physiological implications of cooperative gating of clustered ion channels. Physiol. Rev. 102, 1159–1210 (2022).
Moreno, C. M. et al. Ca(2+) entry into neurons is facilitated by cooperative gating of clustered CaV1.3 channels. Elife 5, e15744 (2016).
Dixon, R. E. et al. Graded Ca2+/calmodulin-dependent coupling of voltage-gated CaV1.2 channels. Elife 4, e05608 (2015).
Dixon, R. E., Yuan, C., Cheng, E. P., Navedo, M. F. & Santana, L. F. Ca2+ signaling amplification by oligomerization of L-type Cav1.2 channels. Proc. Natl Acad. Sci. USA 109, 1749–1754 (2012).
Navedo, M. F. et al. Increased coupled gating of L-type Ca2+ channels during hypertension and Timothy syndrome. Circ. Res. 106, 748–756 (2010).
Navedo, M. F., Amberg, G. C., Votaw, V. S. & Santana, L. F. Constitutively active L-type Ca2+ channels. Proc. Natl Acad. Sci. USA 102, 11112–11117 (2005).
Dickson, E. J. et al. Dynamic formation of ER-PM junctions presents a lipid phosphatase to regulate phosphoinositides. J. Cell Biol. 213, 33–48 (2016).
Söderberg, O. et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3, 995–1000 (2006).
Praggastis, M. et al. A murine Niemann-Pick C1 I1061T knock-in model recapitulates the pathological features of the most prevalent human disease allele. J. Neurosci. 35, 8091–8106 (2015).
Higashi, Y., Murayama, S., Pentchev, P. G. & Suzuki, K. Cerebellar degeneration in the Niemann-Pick type C mouse. Acta Neuropathol. 85, 175–184 (1993).
Yeh, C.-Y. et al. Targeting a potassium channel/syntaxin interaction ameliorates cell death in ischemic stroke. J. Neurosci. 37, 5648–5658 (2017).
Cerda, O. & Trimmer, J. S. Activity-dependent phosphorylation of neuronal Kv2.1 potassium channels by CDK5. J. Biol. Chem. 286, 28738–28748 (2011).
Bu, B., Li, J., Davies, P. & Vincent, I. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci. 22, 6515–6525 (2002).
Nikolic, M., Chou, M. M., Lu, W., Mayer, B. J. & Tsai, L.-H. The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature 395, 194–198 (1998).
Nikolic, M., Dudek, H., Kwon, Y. T., Ramos, Y. F. & Tsai, L. H. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev. 10, 816–825 (1996).
Ling, N. X. Y. et al. mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress. Nat. Metabol. 2, 41–49 (2020).
Fang, K. & Gu, M. Crocin improves insulin sensitivity and ameliorates adiposity by regulating AMPK-CDK5-PPARγ signaling. BioMed Res. Int. 2020, 9136282 (2020).
Vallese, F. et al. An expanded palette of improved SPLICS reporters detects multiple organelle contacts in vitro and in vivo. Nat Commun 11, 6069 (2020).
Chang, C. L. et al. Feedback regulation of receptor-induced Ca2+ signaling mediated by E-Syt1 and Nir2 at endoplasmic reticulum-plasma membrane junctions. Cell Rep. 5, 813–825 (2013).
Panzera, L. C. et al. Activity-dependent endoplasmic reticulum Ca(2+) uptake depends on Kv2.1-mediated endoplasmic reticulum/plasma membrane junctions to promote synaptic transmission. Proc. Natl Acad. Sci. USA 119, e2117135119 (2022).
Jin, L. et al. Single action potentials and subthreshold electrical events imaged in neurons with a fluorescent protein voltage probe. Neuron 75, 779–785 (2012).
Calvo-Rodriguez, M. et al. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer’s disease. Nat. Commun. 11, 2146 (2020).
Kania, E., Roest, G., Vervliet, T., Parys, J. B. & Bultynck, G. IP(3) Receptor-mediated calcium signaling and its role in autophagy in cancer. Frontiers in Oncology 7, 140 (2017).
Cárdenas, C. et al. Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell 142, 270–283 (2010).
Cali, T., Ottolini, D. & Brini, M. Calcium signaling in Parkinson’s disease. Cell Tissue Res. 357, 439–454 (2014).
Giorgi, C., Marchi, S. & Pinton, P. The machineries, regulation and cellular functions of mitochondrial calcium. Nat. Rev. Mol. Cell Biol. 19, 713–730 (2018).
Szabadkai, G. R. et al. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J. Cell Biol. 175, 901–911 (2006).
Thillaiappan, N. B., Chavda, A. P., Tovey, S. C., Prole, D. L. & Taylor, C. W. Ca(2+) signals initiate at immobile IP3 receptors adjacent to ER-plasma membrane junctions. Nat. Commun. 8, 1505 (2017).
de Juan-Sanz, J. et al. Axonal endoplasmic reticulum Ca2+ content controls release probability in CNS nerve terminals. Neuron 93, 867–881.e866 (2017).
Hirabayashi, Y. et al. ER-mitochondria tethering by PDZD8 regulates Ca2+ dynamics in mammalian neurons. Science 358, 623–630 (2017).
Nystoriak, M. A. et al. Ser1928 phosphorylation by PKA stimulates the L-type Ca2+ channel CaV1.2 and vasoconstriction during acute hyperglycemia and diabetes. Sci. Signal 10, eaaf9647 (2017).
Abdel-Khalik, J. et al. Defective cholesterol metabolism in amyotrophic lateral sclerosis. J. Lipid Res. 58, 267–278 (2017).
Rcom-H’cheo-Gauthier, A., Goodwin, J. & Pountney, D. L. Interactions between calcium and alpha-synuclein in neurodegeneration. Biomolecules 4, 795–811 (2014).
Bezprozvanny, I. B. Calcium signaling and neurodegeneration. Acta Naturae 2, 72–82 (2010).
Pathmasiri, K. C. et al. Mass spectrometry imaging and LC/MS reveal decreased cerebellar phosphoinositides in Niemann-Pick type C1-null mice. J. Lipid Res. 61, 1004–1013 (2020).
Murakoshi, H., Shi, G., Scannevin, R. H. & Trimmer, J. S. Phosphorylation of the Kv2.1 K+ channel alters voltage-dependent activation. Mol. Pharmacol. 52, 821–828 (1997).
Medina, D. L. et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat. Cell Biol. 17, 288–299 (2015).
Lloyd-Evans, E. et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 14, 1247–1255 (2008).
Giordano, F. et al. PI(4,5)P(2)-dependent and Ca(2+)-regulated ER-PM interactions mediated by the extended synaptotagmins. Cell 153, 1494–1509 (2013).
Ludtmann, M. H. R. & Abramov, A. Y. Mitochondrial calcium imbalance in Parkinson’s disease. Neurosci. Lett. 663, 86–90 (2018).
Surmeier, D. J. et al. Calcium and Parkinson’s disease. Biochem. Biophys. Res. Commun. 483, 1013–1019 (2017).
Pinton, P., Giorgi, C., Siviero, R., Zecchini, E. & Rizzuto, R. Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene 27, 6407–6418 (2008).
von Lewinski, F. & Keller, B. U. Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci. 28, 494–500 (2005).
Schulien, A. J. et al. Targeted disruption of Kv2.1-VAPA association provides neuroprotection against ischemic stroke in mice by declustering Kv2.1 channels. Sci. Adv. 6, eaaz8110 (2020).
Redman, P. T. et al. Apoptotic surge of potassium currents is mediated by p38 phosphorylation of Kv2.1. Proc. Natl Acad. Sci. USA 104, 3568–3573 (2007).
Pal, S., Hartnett, K. A., Nerbonne, J. M., Levitan, E. S. & Aizenman, E. Mediation of neuronal apoptosis by Kv2.1-encoded potassium channels. J. Neurosci. 23, 4798–4802 (2003).
Malek, M. et al. Inositol triphosphate-triggered calcium release blocks lipid exchange at endoplasmic reticulum-Golgi contact sites. Nat. Commun. 12, 2673 (2021).
Wang, W. A. et al. Loss of calreticulin uncovers a critical role for calcium in regulating cellular lipid homeostasis. Sci. Rep. 7, 5941 (2017).
Casas, M. et al. Sensing of nutrients by CPT1C controls SAC1 activity to regulate AMPA receptor trafficking. J. Cell Biol. 219, e201912045 (2020).
Voelker, T. L. et al. Acute phosphatidylinositol 4,5 bisphosphate depletion destabilizes sarcolemmal expression of cardiac L-type Ca(2+) channel Ca(V)1.2. Proc. Natl Acad. Sci. USA 120, e2221242120 (2023).
Reyes, R. V. et al. The E3 ubiquitin ligase CRL5 regulates dentate gyrus morphogenesis, adult neurogenesis, and animal behavior. Front. Neurosci. 16, 908719 (2022).
Prada, M. P. et al. AKAP5 complex facilitates purinergic modulation of vascular L-type Ca(2+) channel Ca(V)1.2. Nat. Commun. 11, 5303 (2020).
Acknowledgements
The authors are extremely grateful to those laboratories that shared reagents, plasmids, and cells lines used in this study. This work was supported by an Ara Parseghian Medical Research Foundation award (E.J.D.), NIH grants R01 GM127513 and R35 GM149211 (E.J.D.), NIH grant R01 NS131375 (E.J.D and S.S.), NIH grant F32 NS108519 (N.C.V), NIH grant R01 NS109176 (S.S.), NIH grants R01 AG063796 and R01 HL159304 (R.E.D.), and NIH grant R01 NS114210 (J. S. T.). Illustrations were generated using Biorender.com.
Author information
Authors and Affiliations
Contributions
M.C., K.D.M., K.H., and E.J.D. performed experiments. M.C. and E.J.D. performed image analysis. M.C., K.D.M., N.C.V., S.S., J.S.T., R.E.D., and E.J.D. designed experiments. All authors contributed to the writing of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Communications thanks Ilya Bezprozvanny and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Source data
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Casas, M., Murray, K.D., Hino, K. et al. NPC1-dependent alterations in KV2.1–CaV1.2 nanodomains drive neuronal death in models of Niemann-Pick Type C disease. Nat Commun 14, 4553 (2023). https://doi.org/10.1038/s41467-023-39937-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41467-023-39937-w
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.